Chemomab Therapeutics Ltd. American Depositary Share (CMMB)

Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.

Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion. M.D.C. shares surged 17.4% to $62.30 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares rose 137.3% to $0.2246 in pre-market trading after falling 5% on Wednesday. Marpai, Inc. (NASDAQ: MRAI) shares jumped 29% to $1.09 in pre-market trading after declining over 8% on Wednesday. Marpai recently named John Powers as President. Celularity Inc. (NASDAQ: CELU) shares climbed 25.8% to $0.2370 in pre-market trading after falling more than 5% on Wednesday. Phunware, Inc. (NASDAQ: PHUN) shares gained 23% to $0.20 in pre-market trading. Phunware shares dipped 61% on Wednesday after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules. Castellum, Inc. (NYSE: CTM) gained 22.2% ...

Home Depot, Meta Platforms, General Mills, Molson Coors shares were among the big movers on Tuesday.